Two Studies Linking Healthcare Databases with US Cancer Registries
These new studies are designed to examine the potential risk of osteosarcoma among patients treated with teriparatide versus a matched comparator not exposed to teriparatide using linkage between cancer registry data and two healthcare claims databases: (1) Medicare Part D prescription drug claims and (2) an all payer pharmacy claims database from Symphony Health Solutions (SHS). These two new studies will occur in parallel with one another, and run concurrently with the ongoing activities of state cancer registries already participating in the Osteosarcoma Surveillance Study (a retrospective case series study) and the Forteo Patient Registry (a prospective, voluntary patient medication registry), coordinated by RTI Health Solutions (RTI-HS).
Alicia Gilsenan, PHD Senior Director of Epidemiology at RTI-HS and a trained pharmacist
Kirk Midkiff, MPH, Director of Epidemiology within RTI-HS